ValueSet |
ExampleClopidogrelCodes | ACS Example Clopidogrel Codes |
ExamplePrasugrelCodes | ACS Example Prasugrel Codes |
ExampleTicagrelorCodes | ACS Example Ticagrelor Codes |
valueset-aldosterone | Aldosterone Medications Value Set |
valueset-aspirin | Aspirin Medications Value Set |
valueset-betamethasone-exclude | Exclude Betamethasone Medications Value Set |
valueset-betamethasone | Betamethasone Medications Value Set |
valueset-bromfenac-exclude | Exclude Bromfenac Medications Value Set |
valueset-bromfenac | Bromfenac Medications Value Set |
valueset-bumetanide | Bumetanide Medications Value Set |
valueset-celecoxib | Celecoxib Medications Value Set |
valueset-cloprednol | Cloprednol Medications Value Set |
valueset-cortisone | Cortisone Medications Value Set |
valueset-cortivazol | Cortivazol Medications Value Set |
valueset-cyclosporine-exclude | Exclude cyclosporine Medications Value Set |
valueset-cyclosporine | Cyclosporine Medications Value Set |
valueset-deflazacort | Deflazacort Medications Value Set |
valueset-desoxycorticosterone | Desoxycorticosterone Medications Value Set |
valueset-dexamethasone-exclude | Exclude Dexamethasone Medications Value Set |
valueset-dexamethasone | Dexamethasone Medications Value Set |
valueset-dexlansoprazole | Dexlansoprazole Medications Value Set |
valueset-diclofenac-exclude | Exclude Diclofenac Medications Value Set |
valueset-diclofenac | Diclofenac Medications Value Set |
valueset-diflunisal | Diflunisal Medications Value Set |
valueset-digoxin | Digoxin Medications Value Set |
valueset-eplerenone | Eplerenone Medications Value Set |
valueset-esomeprazole | Esomeprazole Medications Value Set |
valueset-ethacrynate | Ethacrynate Medications Value Set |
valueset-etodolac | Etodolac Medications Value Set |
valueset-fenoprofen | Fenoprofen Medications Value Set |
valueset-fludrocortisone | Fludrocortisone Medications Value Set |
valueset-fluocortolone-exclude | Exclude Fluocortolone Medications Value Set |
valueset-fluocortolone | Fluocortolone Medications Value Set |
valueset-flurbiprofen-exclude | Exclude Flurbiprofen Medications Value Set |
valueset-flurbiprofen | Flurbiprofen Medications Value Set |
valueset-furosemide | Furosemide Medications Value Set |
valueset-hydrocortisone-exclude | Exclude Hydrocortisone Medications Value Set |
valueset-hydrocortisone | Hydrocortisone Medications Value Set |
valueset-ibuprofen-exclude | Exclude Ibuprofen Medications Value Set |
valueset-ibuprofen | Ibuprofen Medications Value Set |
valueset-indomethacin | Indomethacin Medications Value Set |
valueset-ketoprofen-exclude | Exclude Ketoprofen Medications Value Set |
valueset-ketoprofen | Ketoprofen Medications Value Set |
valueset-ketorolac-exclude | Exclude Ketorolac Medications Value Set |
valueset-ketorolac | Ketorolac Medications Value Set |
valueset-lansoprazole | Lansoprazole Medications Value Set |
valueset-mefenamate | Mefenamate Medications Value Set |
valueset-meloxicam | Meloxicam Medications Value Set |
valueset-meprednisone | Meprednisone Medications Value Set |
valueset-methylprednisolone-exclude | Exclude Methylprednisolone Medications Value Set |
valueset-methylprednisolone | Methylprednisolone Medications Value Set |
valueset-misoprostol | Misoprostol Medications Value Set |
valueset-nabumetone | Nabumetone Medications Value Set |
valueset-naproxen | Naproxen Medications Value Set |
valueset-nepafenac-exclude | Exclude Nepafenac Medications Value Set |
valueset-nepafenac | Nepafenac Medications Value Set |
valueset-omeprazole | Omeprazole Medications Value Set |
valueset-oxaprozin | Oxaprozin Medications Value Set |
valueset-pantoprazole | Pantoprazole Medications Value Set |
valueset-paramethasone | Paramethasone Medications Value Set |
valueset-piroxicam-exclude | Exclude Piroxicam Medications Value Set |
valueset-piroxicam | Piroxicam Medications Value Set |
valueset-prednisolone-exclude | Exclude Prednisolone Medications Value Set |
valueset-prednisolone | Prednisolone Medications Value Set |
valueset-prednisone | Prednisone Medications Value Set |
valueset-prednylidene | Prednylidene Medications Value Set |
valueset-rabeprazole | Rabeprazole Medications Value Set |
valueset-rimexolone-exclude | Exclude Rimexolone Medications Value Set |
valueset-rimexolone | Rimexolone Medications Value Set |
valueset-spironolactone | Spironolactone Medications Value Set |
valueset-sulindac | Sulindac Medications Value Set |
valueset-tolmetin | Tolmetin Medications Value Set |
valueset-topicaldiclofenac | Topical Diclofenac Medications Value Set |
valueset-torsemide | Torsemide Medications Value Set |
valueset-triamcinolone-exclude | Exclude Triamcinolone Medications Value Set |
valueset-triamcinolone | Triamcinolone Medications Value Set |
valueset-trilostane | Trilostane Medications Value Set |
valueset-warfarin | Warfarin Medications Value Set |
v3-KnowledgeSubjectObservationValue | KnowledgeSubjectObservationValue |
medication-example-uv-ips | Medications - example (IPS) |
amphetamines-class-medications | Amphetamine class medications |
barbiturate-medications | Barbiturate Medications |
benzodiazepine-medications | Benzodiazepine medications |
buprenorphine-and-methadone-medications | Buprenorphine and Methadone medications |
buprenorphine-medications | Buprenorphine Medications |
cns-depressant-medications | CNS depressant medications |
extended-release-opioid-with-ambulatory-misuse-potential | Extended release opioid with ambulatory misuse potential |
fentanyl-type-medications | Fentanyl-type medications |
methadone-medications | Methadone medications |
naloxone-medications | Naloxone medications |
non-synthetic-opioid-medications | Non-synthetic opioid medications |
opioid-analgesics-with-ambulatory-misuse-potential | Opioid analgesics with ambulatory misuse potential |
oxycodone-medications | Oxycodone Medications |
synthetic-opioid-medications | Synthetic opioid medications |
NonPackSemanticDrugVS | Non-Pack Semantic Drug Codes |
SemanticDrugFormGroupVS | Semantic Drug Form Group Codes |
SemanticDrugVS | Semantic Drug Codes |
vn-medication-code | ValueSet dành cho Mã dược phẩm |
Antiarrhythmics | All Antiarrhythmics |
sensitive-condition-codes | ValueSet - Sensitive Condition Codes |
sensitive-medication-codes | ValueSet - Sensitive Medication Codes |
sensitive-medication-request-codes | ValueSet - Sensitive MedicationRequest Codes |
medication-rxnorm-tw | RxNorm藥品代碼值集 |
dataelement-sdcobjectclass | DataElement SDC Object Class |
dataelement-sdcobjectclassproperty | DataElement SDC Object Class Property |
Remdesivir | Remdesivir |
fmc-allergy-code-vs | Fresenius Allergy Code Value Set |
fmc-medication-code-vs | Fresenius Medication Code Value Set |
il-core-medication-code | ILCore Medication Code |
sect_CID_12.html | ImagingContrastAgent |
sect_CID_3850.html | ContrastBolusSubstance |
v3-KnowledgeSubjectObservationValue | KnowledgeSubjectObservationValue |
rtpbc-prescribable-product-code | RTPBC Prescribable Product Code Value Set |
1.3.6.1.4.1.19376.1.7.3.1.1.13.8.144 | Fertility Enhancing Drugs (NCHS) |
1.3.6.1.4.1.19376.1.7.3.1.1.13.8.23 | Augmentation of Labor - Medication (NCHS) |
1.3.6.1.4.1.19376.1.7.3.1.1.13.8.26 | Epidural Anesthesia - Medication (NCHS) |
1.3.6.1.4.1.19376.1.7.3.1.1.13.8.28 | Spinal Anesthesia - Medication (NCHS) |
1.3.6.1.4.1.19376.1.7.3.1.1.13.8.3 | Antibiotics (NCHS) |
1.3.6.1.4.1.19376.1.7.3.1.1.13.8.38 | Glucocortico Steroids (NCHS) |
2.16.840.1.113883.3.88.12.80.16 | Medication Brand Name Value Set |
2.16.840.1.114222.4.11.1103 | Semantic Clinical Drug (Ingredient plus strength and dose form) |
2.16.840.1.114222.4.11.1104 | Semantic Clinical Drug Form (Ingredient plus dose form) |
2.16.840.1.114222.4.11.3120 | Antibiotic Received (Pertussis) |
2.16.840.1.114222.4.11.3147 | Medication Received (VZ) |
2.16.840.1.114222.4.11.3218 | Medication Treatment (TB) |
2.16.840.1.114222.4.11.3311 | Medication Prophylaxis (Malaria) |
2.16.840.1.114222.4.11.3312 | Medication Treatment (Malaria) |
2.16.840.1.114222.4.11.7055 | Antituberculosis Drugs (TB) |
2.16.840.1.114222.4.11.7103 | VPD Laboratory Coded Observation |
2.16.840.1.114222.4.11.7194 | Drugs Used (STD) |
2.16.840.1.114222.4.11.7475 | Epidural/Spinal Anesthesia - Medication (NCHS) |
2.16.840.1.114222.4.11.7539 | Medication Treatment (Babesiosis) |
2.16.840.1.114222.4.11.7619 | Antibiotics (FDD) |
2.16.840.1.114222.4.11.7620 | Antacids (FDD) |
2.16.840.1.114222.4.11.7635 | Medication Administered (FDD) |
2.16.840.1.114222.4.11.7693 | Antibiotic Received (RIBD) |
2.16.840.1.114222.4.11.7700 | AR Agent (RIBD) |
2.16.840.1.114222.4.11.7759 | Medication (TB) |
2.16.840.1.114222.4.11.7834 | Medication Received (TBRD) |
2.16.840.1.114222.4.11.7839 | Medication Received (Lyme) |
2.16.840.1.114222.4.11.7923 | Medication Treatment (STD) |
2.16.840.1.114222.4.11.7954 | Medication Administered (Hansen) |
2.16.840.1.114222.4.11.7961 | Medication (Leptospirosis) |
2.16.840.1.114222.4.11.7963 | Medication Administered (Anthrax) |
2.16.840.1.114222.4.11.7972 | Medication (Brucellosis) |
medication-codes | Medication Clinical Drug (RxNorm) |
substance-rxnorm | DAF Substance RxNorm Codes |
medical-prescriptions | Medical prescriptions |
medication-example-uv-ips | Medications (example) - IPS |
dataelement-sdcobjectclass | DataElement SDC Object Class |
dataelement-sdcobjectclassproperty | DataElement SDC Object Class Property |
dataelement-sdccode | DataElement SDC Concept |
1.3.6.1.4.1.6997.4.1.2.234.13.13.1.16.1.1.999.3 | selected first line medications for pain control |
1.3.6.1.4.1.6997.4.1.2.234.13.13.1.16.1.11.1.999.3 | selected muscle relaxants for pain control |
1.3.6.1.4.1.6997.4.1.2.234.13.13.1.16.1.12.1.999.3 | Selected topical agents for pain control |
1.3.6.1.4.1.6997.4.1.2.234.13.13.1.17.1.1.999.2 | selected non opioids for moderate to severe pain |
1.3.6.1.4.1.6997.4.1.2.234.13.13.1.17.1.11.1.999.2 | Selected opioids for moderate to severe pain |
1.3.6.1.4.1.6997.4.1.2.234.999.3.1 | Opioids used for pain control |
1.3.6.1.4.1.6997.4.1.2.234.999.3.2 | All prescribable opioids used for pain control including Inactive Medications |
1.3.6.1.4.1.6997.4.1.2.265.15.31481.1.12.1.999.251 | Cerumenolytics |
1.3.6.1.4.1.6997.4.1.2.268.13.35211.1.11.1.999.319 | Intranasal Antihistamines |
1.3.6.1.4.1.6997.4.1.2.268.13.35211.1.12.1.999.320 | Mast Cell Stabilizers |
1.3.6.1.4.1.6997.4.1.2.268.13.35211.1.13.1.999.321 | Ophthalmic Antihistamines |
1.3.6.1.4.1.6997.4.1.2.268.15.35221.1.11.1.999.315 | Intranasal Corticosteroids |
1.3.6.1.4.1.6997.4.1.2.268.15.35292.1.1.999.287 | Oral Second Generation and Less Sedating Antihistamines |
1.3.6.1.4.1.6997.4.1.2.268.15.35464.1.1.999.266 | Leukotriene antagonist |
1.3.6.1.4.1.6997.4.1.2.271.12.37641.1.1.999.653 | Fidaxomicin |
1.3.6.1.4.1.6997.4.1.2.271.12.37696.1.1.999.654 | Proton Pump Inhibitors not including for H. pylori treatment |
1.3.6.1.4.1.6997.4.1.2.271.13.38256.1.1.999.662 | Metronidazole Systemic |
1.3.6.1.4.1.6997.4.1.2.271.13.38266.1.1.999.663 | Vancomycin non injectable |
1.3.6.1.4.1.6997.4.1.2.271.15.37872.1.1.999.658 | Antiperistaltic agents to avoid in C. diff |
1.3.6.1.4.1.6997.4.1.2.271.15.37872.1.1.999.734 | Systemic Antimicrobial Medications not used for CDI |
2.16.840.1.113762.1.4.1010.1 | Substance Reactant for Intolerance |
2.16.840.1.113762.1.4.1010.2 | Clinical Substance |
2.16.840.1.113762.1.4.1010.4 | Medication Clinical Drug |
2.16.840.1.113762.1.4.1010.5 | Medication Clinical Brand specific Drug |
2.16.840.1.113762.1.4.1010.7 | Clinical Drug Ingredient |
2.16.840.1.113762.1.4.1010.8 | Vaccine Clinical Drug |
2.16.840.1.113762.1.4.1021.12 | Low Molecular Weight Heparin for VTE prophylaxis ingredient specific |
2.16.840.1.113762.1.4.1032.16 | Low Intensity Statin Therapy/Branded |
2.16.840.1.113762.1.4.1032.17 | Moderate Intensity Statin Therapy/Branded |
2.16.840.1.113762.1.4.1032.18 | High Intensity Statin Therapy/Branded |
2.16.840.1.113762.1.4.1032.26 | Nonopioid pain medications |
2.16.840.1.113762.1.4.1032.303 | Statin Combinations |
2.16.840.1.113762.1.4.1032.313 | Statin Allergen Grouping |
2.16.840.1.113762.1.4.1032.319 | Steward Transfer Test |
2.16.840.1.113762.1.4.1032.320 | Opioids ATCPROD N02A |
2.16.840.1.113762.1.4.1032.34 | Opioid pain medications |
2.16.840.1.113762.1.4.1032.42 | Naloxone and Nalmefene medications |
2.16.840.1.113762.1.4.1032.43 | Benzodiazepine medications |
2.16.840.1.113762.1.4.1032.44 | Stool softeners and laxatives |
2.16.840.1.113762.1.4.1032.54 | Adjuvant pain medications |
2.16.840.1.113762.1.4.1034.467 | Medication Therapy for Cluster Headache (RXNORM) |
2.16.840.1.113762.1.4.1034.558 | Acute Cluster Headache Medication (RXNORM) |
2.16.840.1.113762.1.4.1034.559 | Long Term Preventive Medication for Cluster Headache |
2.16.840.1.113762.1.4.1034.561 | Oral Steroid for Cluster Headache |
2.16.840.1.113762.1.4.1034.569 | Migraine Preventive Medication |
2.16.840.1.113762.1.4.1034.601 | Acute Migraine Attack Medication |
2.16.840.1.113762.1.4.1034.605 | NSAID OTC Migraine Attack Medication |
2.16.840.1.113762.1.4.1034.606 | NSAID Prescribable Migraine Attack Medication |
2.16.840.1.113762.1.4.1034.643 | Antiplatelets |
2.16.840.1.113762.1.4.1034.644 | Anticoagulants |
2.16.840.1.113762.1.4.1034.645 | Statin Medications |
2.16.840.1.113762.1.4.1034.651 | Galcanezumab (RxNorm) |
2.16.840.1.113762.1.4.1034.652 | Lithium (RxNorm) |
2.16.840.1.113762.1.4.1034.653 | Verapamil |
2.16.840.1.113762.1.4.1034.654 | Long term preventive medications for cluster headache |
2.16.840.1.113762.1.4.1034.655 | Short term preventive medication for cluster headache |
2.16.840.1.113762.1.4.1034.656 | Zolmitriptan |
2.16.840.1.113762.1.4.1034.657 | Sumatriptan |
2.16.840.1.113762.1.4.1034.658 | Dihydroergotamine |
2.16.840.1.113762.1.4.1034.659 | Acute cluster headache medication |
2.16.840.1.113762.1.4.1034.664 | Prescribable NSAIDs and Acute Migraine Attack Medication |
2.16.840.1.113762.1.4.1045.39 | Low Dose Unfractionated Heparin for VTE Prophylaxis |
2.16.840.1.113762.1.4.1045.41 | Glycoprotein IIb IIIa Inhibitors |
2.16.840.1.113762.1.4.1045.55 | Oxytocin |
2.16.840.1.113762.1.4.1045.56 | Dinoprostone |
2.16.840.1.113762.1.4.1046.241 | Schedule II, III and IV Opioid Medications |
2.16.840.1.113762.1.4.1046.269 | Medications for Opioid Use Disorder (MOUD) |
2.16.840.1.113762.1.4.1047.107 | Low Intensity Statin Therapy |
2.16.840.1.113762.1.4.1047.543 | Bevacizumab injection |
2.16.840.1.113762.1.4.1047.544 | Ranibizumab injection |
2.16.840.1.113762.1.4.1047.545 | Aflibercept injection |
2.16.840.1.113762.1.4.1047.557 | Corticosteroids for Injection |
2.16.840.1.113762.1.4.1047.582 | Corticosteroids for Injection |
2.16.840.1.113762.1.4.1047.97 | High Intensity Statin Therapy |
2.16.840.1.113762.1.4.1047.98 | Moderate Intensity Statin Therapy |
2.16.840.1.113762.1.4.1078.10 | ARBs (Angiotensin Receptor Blockers) |
2.16.840.1.113762.1.4.1078.1000 | OIA_V2_GLP1s_RxNorms |
2.16.840.1.113762.1.4.1078.1001 | OIA_V2_PCSK9s_RxNorms |
2.16.840.1.113762.1.4.1078.1006 | OIA_Asthma_COPD_Combo_Meds |
2.16.840.1.113762.1.4.1078.1007 | OIA_Asthma_COPD_Combo_Meds_SABA_SAMA |
2.16.840.1.113762.1.4.1078.1008 | OIA_Asthma_COPD_Combo_Meds_LABA_LAMA_ICS |
2.16.840.1.113762.1.4.1078.1016 | OIA_TEST_VS |
2.16.840.1.113762.1.4.1078.1032 | Beta blocker allergy intolerance |
2.16.840.1.113762.1.4.1078.1046 | AZT Meds |
2.16.840.1.113762.1.4.1078.1056 | OIA_Antiemetics |
2.16.840.1.113762.1.4.1078.1057 | OIA_PDE5is |
2.16.840.1.113762.1.4.1078.1058 | OIA_Vitamins |
2.16.840.1.113762.1.4.1078.1059 | OIA_Plavix |
2.16.840.1.113762.1.4.1078.1061 | OIA_Oral_Contraceptives |
2.16.840.1.113762.1.4.1078.1063 | OIA_Topical_Steroids |
2.16.840.1.113762.1.4.1078.1064 | OIA_Cough_Cold_Meds |
2.16.840.1.113762.1.4.1078.1065 | Antiperspirant aluminum salts |
2.16.840.1.113762.1.4.1078.1066 | Antiperspirant anticholinergics |
2.16.840.1.113762.1.4.1078.1067 | Antieplieptic medications |
2.16.840.1.113762.1.4.1078.1068 | Antidepressant medications |
2.16.840.1.113762.1.4.1078.1088 | ET propanolol or primidone |
2.16.840.1.113762.1.4.1078.1089 | ET topiramate alprazolam or gabapentin |
2.16.840.1.113762.1.4.1078.146 | Long Acting Muscarinic Antagonists (LAMA) |
2.16.840.1.113762.1.4.1078.168 | medications_COPD |
2.16.840.1.113762.1.4.1078.186 | Beta blockers GDMT for heart failure |
2.16.840.1.113762.1.4.1078.188 | medications_heart failure |
2.16.840.1.113762.1.4.1078.189 | SGLT2i |
2.16.840.1.113762.1.4.1078.238 | MRA mineralocorticoid receptor antagonists |
2.16.840.1.113762.1.4.1078.282 | Statin Allergy Intolerance |
2.16.840.1.113762.1.4.1078.367 | Trandolapril |
2.16.840.1.113762.1.4.1078.369 | Candesartan |
2.16.840.1.113762.1.4.1078.377 | Valsartan |
2.16.840.1.113762.1.4.1078.412 | Statin Moderate Intensity |
2.16.840.1.113762.1.4.1078.434 | Insulin |
2.16.840.1.113762.1.4.1078.437 | TZD Thiazolidinediones |
2.16.840.1.113762.1.4.1078.438 | medications_T2DM |
2.16.840.1.113762.1.4.1078.45 | ACE inhibitor allergy RXNORM |
2.16.840.1.113762.1.4.1078.473 | Tetanus toxoid, diphtheria (Td) Vaccine |
2.16.840.1.113762.1.4.1078.481 | medications_hypertension |
2.16.840.1.113762.1.4.1078.527 | OCS_Prednisone |
2.16.840.1.113762.1.4.1078.528 | High Dose Non Combo ICS Adult |
2.16.840.1.113762.1.4.1078.529 | Medium Dose Non Combo Asthma ICS Adult |
2.16.840.1.113762.1.4.1078.530 | Low Dose Non Combo ICS |
2.16.840.1.113762.1.4.1078.531 | Anti IgE Medications |
2.16.840.1.113762.1.4.1078.532 | IL5 Antagonists |
2.16.840.1.113762.1.4.1078.533 | Mast cell stabilizers for asthma |
2.16.840.1.113762.1.4.1078.552 | Triptans |
2.16.840.1.113762.1.4.1078.553 | CGRP receptor antagonists |
2.16.840.1.113762.1.4.1078.554 | Ditans |
2.16.840.1.113762.1.4.1078.555 | Ergots |
2.16.840.1.113762.1.4.1078.556 | Migraine specific NSAIDs |
2.16.840.1.113762.1.4.1078.557 | OTC migraine analgesics |
2.16.840.1.113762.1.4.1078.558 | Butalbital analgesics |
2.16.840.1.113762.1.4.1078.559 | medications_migraine_acute |
2.16.840.1.113762.1.4.1078.565 | Triptan Allergy Intolerance |
2.16.840.1.113762.1.4.1078.569 | Allergen Immunotherapy |
2.16.840.1.113762.1.4.1078.578 | PIM_Schedule V |
2.16.840.1.113762.1.4.1078.580 | PIM_Acarbose |
2.16.840.1.113762.1.4.1078.581 | PIM_Avandamet |
2.16.840.1.113762.1.4.1078.582 | PIM_Dulaglutide |
2.16.840.1.113762.1.4.1078.583 | PIM_Glimepiride |
2.16.840.1.113762.1.4.1078.585 | PIM_Glucophage |
2.16.840.1.113762.1.4.1078.587 | PIM_Glucovance |
2.16.840.1.113762.1.4.1078.588 | Glyburide PIM |
2.16.840.1.113762.1.4.1078.590 | Alpha glucosidase inhibitors |
2.16.840.1.113762.1.4.1078.595 | ICS Low |
2.16.840.1.113762.1.4.1078.596 | ICS Medium |
2.16.840.1.113762.1.4.1078.597 | ICS High |
2.16.840.1.113762.1.4.1078.598 | Low Dose ICS Formoterol |
2.16.840.1.113762.1.4.1078.604 | PIM_Glyburide |
2.16.840.1.113762.1.4.1078.605 | PIM_Pioglitazone |
2.16.840.1.113762.1.4.1078.606 | PIM_Semaglutide |
2.16.840.1.113762.1.4.1078.607 | PIM_Linagliptin |
2.16.840.1.113762.1.4.1078.609 | Macrolide_Azithromycin |
2.16.840.1.113762.1.4.1078.61 | Secondary antihypertensives |
2.16.840.1.113762.1.4.1078.610 | Long Acting Beta Agonists (LABA) Non_Formoterol |
2.16.840.1.113762.1.4.1078.615 | medications_Asthma |
2.16.840.1.113762.1.4.1078.617 | HighICS_LABA_NonFormoterol |
2.16.840.1.113762.1.4.1078.619 | ICS_LABA_LAMA |
2.16.840.1.113762.1.4.1078.620 | Low Dose ICS_LABA_Non Formoterol |
2.16.840.1.113762.1.4.1078.621 | Medium ICS_LABA Non Formoterol |
2.16.840.1.113762.1.4.1078.642 | T2DM_Medications Allergy RXNORM |
2.16.840.1.113762.1.4.1078.646 | T2DM_Medication Allergy Intolerance |
2.16.840.1.113762.1.4.1078.647 | Statins Allergy Intolerance |
2.16.840.1.113762.1.4.1078.649 | ACE Inhibitors Allergy Intolerance |
2.16.840.1.113762.1.4.1078.650 | ARB Allergy Intolerance |
2.16.840.1.113762.1.4.1078.652 | Long Acting Muscarinic Antagonists (LAMA) Allergy Intolerance |
2.16.840.1.113762.1.4.1078.653 | Long Acting Beta Agonists (LABA) Allergy Intolerance |
2.16.840.1.113762.1.4.1078.654 | BetaBlocker NonCS Secondary Allergy Intolerance |
2.16.840.1.113762.1.4.1078.656 | MRA Allergy Intolerance |
2.16.840.1.113762.1.4.1078.657 | Eplerenone Allergy Intolerance |
2.16.840.1.113762.1.4.1078.658 | Spironolactone Allergy Intolerance |
2.16.840.1.113762.1.4.1078.659 | SGLT2i Allergy Intolerance |
2.16.840.1.113762.1.4.1078.660 | Angiotensin Receptor Neprilysin Inhibitor(ARNI) Allergy Intolerance |
2.16.840.1.113762.1.4.1078.661 | Tetanus, Diphtheria, Pertusis (Tdap) Vaccine Allergy Intolerance |
2.16.840.1.113762.1.4.1078.665 | Tetanus toxoid, diphtheria (Td) Vaccine Allergy Intolerance |
2.16.840.1.113762.1.4.1078.666 | Human Papillomavirus (HPV) vaccine Allergy Intolerance |
2.16.840.1.113762.1.4.1078.667 | Herpes Zoster Vaccine Allergy Intolerance |
2.16.840.1.113762.1.4.1078.670 | Pneumococcal Vaccine Allergy Intolerance |
2.16.840.1.113762.1.4.1078.671 | Inhaled Corticosteroids(ICS) Allergy Intolerance |
2.16.840.1.113762.1.4.1078.672 | LABA(Formoterol only) |
2.16.840.1.113762.1.4.1078.674 | PIM_Tirzepatide |
2.16.840.1.113762.1.4.1078.675 | GLP1RA Allergy Intolerance |
2.16.840.1.113762.1.4.1078.677 | PIM_H2_Antagonists |
2.16.840.1.113762.1.4.1078.678 | SGLT2i DM CKD |
2.16.840.1.113762.1.4.1078.679 | SGLT2i DM ASCVD |
2.16.840.1.113762.1.4.1078.680 | GLP1RA DM ASCVD |
2.16.840.1.113762.1.4.1078.683 | OIA_Gout_Medications |
2.16.840.1.113762.1.4.1078.684 | GlumetzaSubstitution |
2.16.840.1.113762.1.4.1078.685 | MetforminER500mg |
2.16.840.1.113762.1.4.1078.686 | PIM_Metformin |
2.16.840.1.113762.1.4.1078.687 | PIM_Glipizide |
2.16.840.1.113762.1.4.1078.689 | PIM_Glipizide_Glyburide_Glimepiride |
2.16.840.1.113762.1.4.1078.690 | PIM_Insulin_Meglitinides |
2.16.840.1.113762.1.4.1078.691 | PIM_Glyxambi |
2.16.840.1.113762.1.4.1078.692 | PIM_Farxiga |
2.16.840.1.113762.1.4.1078.693 | PIM_Invokana |
2.16.840.1.113762.1.4.1078.694 | PIM_Jardiance |
2.16.840.1.113762.1.4.1078.695 | PIM_Invokana_Jardiance |
2.16.840.1.113762.1.4.1078.696 | Reclast |
2.16.840.1.113762.1.4.1078.697 | LAMA_LABA Combination 1 Inhaler |
2.16.840.1.113762.1.4.1078.698 | PIM_Contraceptives |
2.16.840.1.113762.1.4.1078.699 | Selected Oral Antiemetics for Migraine |
2.16.840.1.113762.1.4.1078.702 | PIM_SSRIs |
2.16.840.1.113762.1.4.1078.703 | PIM_SNRIs |
2.16.840.1.113762.1.4.1078.704 | PIM_NRIs |
2.16.840.1.113762.1.4.1078.705 | PIM_TCAs |
2.16.840.1.113762.1.4.1078.706 | PIM_Citalopram |
2.16.840.1.113762.1.4.1078.707 | PIM_Hydroxyzine |
2.16.840.1.113762.1.4.1078.708 | PIM_Buspirone |
2.16.840.1.113762.1.4.1078.709 | PIM_Bupropion |
2.16.840.1.113762.1.4.1078.710 | PIM_Mirtazapine |
2.16.840.1.113762.1.4.1078.711 | PIM_Trazodone |
2.16.840.1.113762.1.4.1078.714 | PIM_Gabapentin |
2.16.840.1.113762.1.4.1078.715 | PIM_Allergy_Nasal_Sprays |
2.16.840.1.113762.1.4.1078.716 | PIM_Allergy_Oral_Meds |
2.16.840.1.113762.1.4.1078.717 | PIM_Allergy_Nasal_Oral |
2.16.840.1.113762.1.4.1078.719 | OCS_Prednisolone |
2.16.840.1.113762.1.4.1078.72 | Inhaled corticosteroids (IC) |
2.16.840.1.113762.1.4.1078.720 | COPD_Ofloxacin |
2.16.840.1.113762.1.4.1078.721 | COPD_Ciprofloxacin |
2.16.840.1.113762.1.4.1078.722 | COPD_Doxycycline |
2.16.840.1.113762.1.4.1078.724 | Macrolide Allergy Intolerance |
2.16.840.1.113762.1.4.1078.728 | Tetracycline Allergy Intolerance |
2.16.840.1.113762.1.4.1078.730 | Fluoroquinolone Allergy Intolerance |
2.16.840.1.113762.1.4.1078.731 | Penicillin Allergy RXNORM |
2.16.840.1.113762.1.4.1078.733 | Penicillin Allergy Intolerance |
2.16.840.1.113762.1.4.1078.734 | PIM_Metformin_Single_Ingredient_Only |
2.16.840.1.113762.1.4.1078.735 | PIM_Metformin_Combo_Ingredient_Only |
2.16.840.1.113762.1.4.1078.779 | PIM_Potassium_Supplements |
2.16.840.1.113762.1.4.1078.780 | PIM_PPIs |
2.16.840.1.113762.1.4.1078.781 | PIM_Migraine_Medications_Abortive |
2.16.840.1.113762.1.4.1078.782 | PIM_Migraine_Medications_Preventive |
2.16.840.1.113762.1.4.1078.783 | PIM_Bisphosphonates |
2.16.840.1.113762.1.4.1078.784 | PIM_BPH_Medications |
2.16.840.1.113762.1.4.1078.785 | PIM_Thyroid_Replacement_Medications |
2.16.840.1.113762.1.4.1078.786 | PIM_Overactive_Bladder_Medications |
2.16.840.1.113762.1.4.1078.787 | PIM_Topical_Acne_Medications |
2.16.840.1.113762.1.4.1078.788 | PIM_Antidepressant_Anxiolytic_Medications |
2.16.840.1.113762.1.4.1078.823 | Aminoglycosides |
2.16.840.1.113762.1.4.1078.824 | Carbapenems |
2.16.840.1.113762.1.4.1078.826 | Monobactams |
2.16.840.1.113762.1.4.1078.827 | Penicillins |
2.16.840.1.113762.1.4.1078.828 | Antimycobacterials |
2.16.840.1.113762.1.4.1078.829 | Beta_lactamase |
2.16.840.1.113762.1.4.1078.830 | Cyclic lipopeptides |
2.16.840.1.113762.1.4.1078.831 | Lincosamides |
2.16.840.1.113762.1.4.1078.832 | Macrolides |
2.16.840.1.113762.1.4.1078.833 | Amphenicol |
2.16.840.1.113762.1.4.1078.834 | Oxazolidinones |
2.16.840.1.113762.1.4.1078.835 | Fluoroquinolones |
2.16.840.1.113762.1.4.1078.836 | Sulfonamides |
2.16.840.1.113762.1.4.1078.837 | Tetracyclines |
2.16.840.1.113762.1.4.1078.838 | Phosphonics |
2.16.840.1.113762.1.4.1078.839 | Pleuromutilin |
2.16.840.1.113762.1.4.1078.840 | Streptogramins |
2.16.840.1.113762.1.4.1078.841 | Lipoglycopeptides |
2.16.840.1.113762.1.4.1078.842 | Nitroimidazoles |
2.16.840.1.113762.1.4.1078.843 | PIM_Hyd_Bus_Mir_Tra |
2.16.840.1.113762.1.4.1078.844 | Nitrofurans |
2.16.840.1.113762.1.4.1078.845 | Rifamycins |
2.16.840.1.113762.1.4.1078.846 | Glycylcycline |
2.16.840.1.113762.1.4.1078.847 | Pyrimidines |
2.16.840.1.113762.1.4.1078.849 | Antibiotics oral and parenteral |
2.16.840.1.113762.1.4.1078.85 | PCSK9i |
2.16.840.1.113762.1.4.1078.850 | Medications_hyperkalemia |
2.16.840.1.113762.1.4.1078.855 | Medications_Chronic Hyperkalemia |
2.16.840.1.113762.1.4.1078.858 | PIM_Alpha_Blockers_2 |
2.16.840.1.113762.1.4.1078.869 | PIM_Migraine_Medications |
2.16.840.1.113762.1.4.1078.870 | PIM_Triptans |
2.16.840.1.113762.1.4.1078.871 | ICS_SABA Reliever |
2.16.840.1.113762.1.4.1078.873 | PIM_Asthma_COPD_Meds |
2.16.840.1.113762.1.4.1078.876 | Alpha Glucosidase Allergy Intolerance |
2.16.840.1.113762.1.4.1078.883 | DPP4i Allergy Intolerance |
2.16.840.1.113762.1.4.1078.890 | Meglitinide Allergy Intolerance |
2.16.840.1.113762.1.4.1078.891 | Sulfonylurea Allergy Intolerance |
2.16.840.1.113762.1.4.1078.895 | TZD Allergy Intolerance |
2.16.840.1.113762.1.4.1078.896 | PIM_Beta_Blockers |
2.16.840.1.113762.1.4.1078.897 | PIM_CCB_DHPs |
2.16.840.1.113762.1.4.1078.898 | PIM_Loop_Diuretics |
2.16.840.1.113762.1.4.1078.899 | PIM_Inhaled_Corticosteroids_(ICS) |
2.16.840.1.113762.1.4.1078.9 | ACE inhibitors |
2.16.840.1.113762.1.4.1078.900 | PIM_Leukotrienes |
2.16.840.1.113762.1.4.1078.901 | OIA_Asthma_COPD_Meds_Inhalers |
2.16.840.1.113762.1.4.1078.902 | OIA_Asthma_COPD_Meds_Nebulizers |
2.16.840.1.113762.1.4.1078.903 | OIA_Asthma_COPD_Meds_Oral |
2.16.840.1.113762.1.4.1078.904 | OIA_GLP1_Injectables |
2.16.840.1.113762.1.4.1078.905 | OIA_Insulin_Injectables |
2.16.840.1.113762.1.4.1078.906 | OIA_Oral_Hypoglycemics |
2.16.840.1.113762.1.4.1078.907 | OIA_DM1_DM2_Meds |
2.16.840.1.113762.1.4.1078.908 | Medium Dose ICS Formoterol |
2.16.840.1.113762.1.4.1078.909 | High Dose ICS Formoterol |
2.16.840.1.113762.1.4.1078.926 | Canagliflozin meds |
2.16.840.1.113762.1.4.1078.927 | Empagliflozin meds |
2.16.840.1.113762.1.4.1078.928 | Dapagliflozin meds |
2.16.840.1.113762.1.4.1078.929 | Ertugliflozin meds |
2.16.840.1.113762.1.4.1078.930 | Dulaglutide meds |
2.16.840.1.113762.1.4.1078.931 | Liraglutide meds |
2.16.840.1.113762.1.4.1078.932 | Semaglutide SC meds |
2.16.840.1.113762.1.4.1078.933 | T2DM meds benefitting ASCVD |
2.16.840.1.113762.1.4.1078.934 | T2DM meds benefitting CKD stages 2, 3, and 4 with eGFR >= 20 mL/min |
2.16.840.1.113762.1.4.1078.935 | T2DM meds benefitting CKD stage 5 |
2.16.840.1.113762.1.4.1078.936 | T2DM meds benefitting HF with eGFR >= 20 mL/min |
2.16.840.1.113762.1.4.1078.944 | OIA_Bisoprolol |
2.16.840.1.113762.1.4.1078.947 | OIA_Antihypertensive_Medications |
2.16.840.1.113762.1.4.1078.959 | ACEi for HFrEF |
2.16.840.1.113762.1.4.1078.960 | ARB for HFrEF |
2.16.840.1.113762.1.4.1078.961 | OIA_AntiHTN_Meds_Inclusion_List |
2.16.840.1.113762.1.4.1078.962 | OIA_Thiazide_Diuretics |
2.16.840.1.113762.1.4.1078.971 | Pioglitazone |
2.16.840.1.113762.1.4.1078.975 | OIA_Sulfonylureas |
2.16.840.1.113762.1.4.1078.976 | Ensifentrine |
2.16.840.1.113762.1.4.1078.977 | Dupilumab |
2.16.840.1.113762.1.4.1110.42 | Statin Allergen |
2.16.840.1.113762.1.4.1110.50 | Rivaroxaban for VTE Prophylaxis |
2.16.840.1.113762.1.4.1110.51 | Prasugrel |
2.16.840.1.113762.1.4.1110.52 | Pharmacological Contraindications For Antithrombotic Therapy |
2.16.840.1.113762.1.4.1110.61 | Antithrombotic Therapy Antiplatelet |
2.16.840.1.113762.1.4.1110.62 | Antithrombotic Therapy for Ischemic Stroke |
2.16.840.1.113762.1.4.1111.146 | Buprenorphine |
2.16.840.1.113762.1.4.1111.166 | Codeine Schedule II and III |
2.16.840.1.113762.1.4.1111.167 | Alfentanil |
2.16.840.1.113762.1.4.1111.168 | Remifentanil |
2.16.840.1.113762.1.4.1111.169 | Sufentanil |
2.16.840.1.113762.1.4.1116.1 | Rituximab Injectable |
2.16.840.1.113762.1.4.1116.151 | Cisplatin Injectable |
2.16.840.1.113762.1.4.1116.153 | Vinorelbine Injectable |
2.16.840.1.113762.1.4.1116.154 | Gemcitabine Injectable |
2.16.840.1.113762.1.4.1116.155 | Docetaxel |
2.16.840.1.113762.1.4.1116.156 | Pemetrexed Injectable |
2.16.840.1.113762.1.4.1116.158 | Vinblastine Injectable |
2.16.840.1.113762.1.4.1116.165 | Carboplatin Injectable |
2.16.840.1.113762.1.4.1116.166 | Paclitaxel |
2.16.840.1.113762.1.4.1116.168 | Doxorubicin Injectable |
2.16.840.1.113762.1.4.1116.169 | Irinotecan Injectable |
2.16.840.1.113762.1.4.1116.179 | Bevacizumab Injectable |
2.16.840.1.113762.1.4.1116.181 | Methotrexate |
2.16.840.1.113762.1.4.1116.194 | Pertuzumab Injectable |
2.16.840.1.113762.1.4.1116.196 | Ixabepilone Injectable |
2.16.840.1.113762.1.4.1116.197 | Goserelin |
2.16.840.1.113762.1.4.1116.200 | Epirubicin Injectable |
2.16.840.1.113762.1.4.1116.202 | Ramucirumab Injectable |
2.16.840.1.113762.1.4.1116.204 | Letrozole |
2.16.840.1.113762.1.4.1116.206 | Exemestane |
2.16.840.1.113762.1.4.1116.209 | Fluorouracil |
2.16.840.1.113762.1.4.1116.210 | Capecitabine Oral |
2.16.840.1.113762.1.4.1116.222 | Aprepitant Oral |
2.16.840.1.113762.1.4.1116.223 | Fosaprepitant Injectable |
2.16.840.1.113762.1.4.1116.257 | Colorectal Cancer Chemotherapy |
2.16.840.1.113762.1.4.1116.332 | Daunorubicin Injectable |
2.16.840.1.113762.1.4.1116.336 | Palonosetron Injectable |
2.16.840.1.113762.1.4.1116.449 | Opioids |
2.16.840.1.113762.1.4.1116.492 | Pharmacological interventions for depression |
2.16.840.1.113762.1.4.1116.560 | Rolapitant Oral |
2.16.840.1.113762.1.4.1116.599 | Obinutuzumab Injectable |
2.16.840.1.113762.1.4.1116.600 | Ofatumumab Injectable |
2.16.840.1.113762.1.4.1116.602 | Neurokinin 1 Receptor Antagonist |
2.16.840.1.113762.1.4.1116.604 | Serotonin Receptor Antagonist |
2.16.840.1.113762.1.4.1116.61 | Cetuximab Injectable |
2.16.840.1.113762.1.4.1116.63 | Panitumumab Injectable |
2.16.840.1.113762.1.4.1116.81 | Palonosetron Oral |
2.16.840.1.113762.1.4.1125.1 | Schedule IV Benzodiazepines |
2.16.840.1.113762.1.4.1142.26 | C2S HIV/AIDS Information Sensitivity |
2.16.840.1.113762.1.4.1142.3 | C2S Alcohol Use Disorders |
2.16.840.1.113762.1.4.1142.35 | C2S Mental Health Disorders |
2.16.840.1.113762.1.4.1142.52 | C2S Tobacco Use Disorders |
2.16.840.1.113762.1.4.1142.58 | C2S Sensitive Categories |
2.16.840.1.113762.1.4.1146.1053 | Carbidopa Levodopa Combination (RXNORM) |
2.16.840.1.113762.1.4.1146.1078 | Opioid Overdose and Poisoning (Naloxone) (RxNorm) |
2.16.840.1.113762.1.4.1146.1594 | HIV Infection (ARV Nucleoside Reverse Transcriptase Inhibitors [NRTIs]) (RXNORM) |
2.16.840.1.113762.1.4.1146.1595 | HIV Infection (ARV Non nucleoside Reverse Transcriptase Inhibitors [NNRTIs]) (RXNORM) |
2.16.840.1.113762.1.4.1146.1597 | HIV Infection (ARV Combination Treatment for HIV) (RXNORM) |
2.16.840.1.113762.1.4.1146.1598 | HIV Infection (ARV Protease Inhibitors [PIs]) (RXNORM) |
2.16.840.1.113762.1.4.1146.1600 | HIV Infection (ARV Integrase Strand Transfer Inhibitors [INSTIs]) (RXNORM) |
2.16.840.1.113762.1.4.1146.1618 | Smallpox Vaccine (RXNORM) |
2.16.840.1.113762.1.4.1146.1634 | Sofosbuvir Velpatasvir Combination (RXNORM) |
2.16.840.1.113762.1.4.1146.1912 | Penicillin G [Aqueous Crystalline] [Injectable] (RXNORM) |
2.16.840.1.113762.1.4.1146.1913 | Penicillin G [Procaine] [Injectable] (RXNORM) |
2.16.840.1.113762.1.4.1146.2142 | Linezolid (RXNORM) |
2.16.840.1.113762.1.4.1146.2143 | Tuberculosis (Pretomanid) (RXNORM) |
2.16.840.1.113762.1.4.1146.2144 | Tuberculosis (Bedaquiline) (RXNORM) |
2.16.840.1.113762.1.4.1146.2362 | Tuberculosis (Ethambutol) (RXNORM) |
2.16.840.1.113762.1.4.1146.2363 | Tuberculosis (Isoniazid [INH]) (RXNORM) |
2.16.840.1.113762.1.4.1146.2364 | Tuberculosis (Pyrazinamide [PZA]) (RXNORM) |
2.16.840.1.113762.1.4.1146.2365 | Tuberculosis (Rifabutin) (RXNORM) |
2.16.840.1.113762.1.4.1146.2366 | Tuberculosis (Rifampin) (RXNORM) |
2.16.840.1.113762.1.4.1146.2367 | Tuberculosis (Rifapentine) (RXNORM) |
2.16.840.1.113762.1.4.1146.741 | Hepatitis B Immune Globulin (RXNORM) |
2.16.840.1.113762.1.4.1146.747 | Penicillin G [Benzathine] [Injectable] [Bicillin] (RXNORM) |
2.16.840.1.113762.1.4.1146.844 | Tuberculosis (Second Line Drugs for Treatment) (RXNORM) |
2.16.840.1.113762.1.4.1146.991 | Rifampin (RXNORM) |
2.16.840.1.113762.1.4.1147.130 | Anticoagulants for VTE Prophylaxis |
2.16.840.1.113762.1.4.1147.131 | Anticoagulants for Indications Other than VTE Prophylaxis |
2.16.840.1.113762.1.4.1151.32 | Immunosuppressive Drugs for Urology Care |
2.16.840.1.113762.1.4.1151.4 | BCG Bacillus Calmette Guerin, Tice |
2.16.840.1.113762.1.4.1151.48 | Androgen deprivation therapy for Urology Care |
2.16.840.1.113762.1.4.1151.5 | BCG Bacillus Calmette Guerin, Connaught |
2.16.840.1.113762.1.4.1151.52 | BCG Bacillus Calmette Guerin for Urology Care |
2.16.840.1.113762.1.4.1151.60 | Chemotherapy Agents for Advanced Cancer |
2.16.840.1.113762.1.4.1160.43 | Analgesics for Acute Pain |
2.16.840.1.113762.1.4.1160.57 | Aldosterone Receptor Blocker for Hypertension |
2.16.840.1.113762.1.4.1160.58 | Alpha Blocker for Hypertension |
2.16.840.1.113762.1.4.1160.59 | Angiotensin Converting Enzyme Inhibitor for Hypertension |
2.16.840.1.113762.1.4.1160.60 | Angiotensin II Receptor Blocker for Hypertension |
2.16.840.1.113762.1.4.1160.61 | Beta Blocker for Hypertension |
2.16.840.1.113762.1.4.1160.62 | Calcium Channel Blocker Dihydropyridine for Hypertension |
2.16.840.1.113762.1.4.1160.63 | Calcium Channel Blocker Non Dihydropyridine for Hypertension |
2.16.840.1.113762.1.4.1160.64 | Central Acting for Hypertension |
2.16.840.1.113762.1.4.1160.65 | Direct Renin Inhibitor for Hypertension |
2.16.840.1.113762.1.4.1160.66 | Loop Diuretic for Hypertension |
2.16.840.1.113762.1.4.1160.67 | Neuronal Blocking Agent for Hypertension |
2.16.840.1.113762.1.4.1160.68 | Potassium Sparing Diuretic for Hypertension |
2.16.840.1.113762.1.4.1160.69 | Thiazide Diuretic for Hypertension |
2.16.840.1.113762.1.4.1160.70 | Vasodilator for Hypertension |
2.16.840.1.113762.1.4.1160.73 | Analgesics for Acute Pain (Non Parenteral Route) |
2.16.840.1.113762.1.4.1160.74 | Analgesics for Acute Pain (Parenteral Route) |
2.16.840.1.113762.1.4.1160.75 | Analgesics for Acute Pain Non Oral Enteral/Mucosal Routes |
2.16.840.1.113762.1.4.1160.77 | Antihypertensive Medication Classes |
2.16.840.1.113762.1.4.1166.129 | Contraceptive Ring RXNORM Medications |
2.16.840.1.113762.1.4.1166.130 | Contraceptive Implants RXNORM Medications |
2.16.840.1.113762.1.4.1166.131 | Injectable Contraceptive RXNORM Medications |
2.16.840.1.113762.1.4.1166.132 | Oral Contraceptive Pills RXNORM Medications |
2.16.840.1.113762.1.4.1166.76 | Contraceptive Patch RXNORM Medications |
2.16.840.1.113762.1.4.1166.85 | Intrauterine Devices RXNORM Medications |
2.16.840.1.113762.1.4.1170.4 | Thrombolytic medications |
2.16.840.1.113762.1.4.1178.1 | Ezetimibe Therapy |
2.16.840.1.113762.1.4.1178.10 | Antihypertensive Medications |
2.16.840.1.113762.1.4.1178.139 | AHA GWTG Anti Obesity Pharmacotherapy |
2.16.840.1.113762.1.4.1178.16 | Antihypertensive Fixed Dose Combination Medications |
2.16.840.1.113762.1.4.1178.2 | PCSK9 Inhibitors |
2.16.840.1.113762.1.4.1178.20 | CCB and Thiazide and Thiazide Like Diuretics |
2.16.840.1.113762.1.4.1178.27 | ARNI Therapy |
2.16.840.1.113762.1.4.1178.29 | MRA Therapy |
2.16.840.1.113762.1.4.1178.30 | SGLT2 Inhibitors |
2.16.840.1.113762.1.4.1178.35 | Aspirin or Clopidogrel |
2.16.840.1.113762.1.4.1178.43 | SGLT2 Ingredients |
2.16.840.1.113762.1.4.1178.44 | MRA Ingredients |
2.16.840.1.113762.1.4.1178.72 | ARNI Ingredient |
2.16.840.1.113762.1.4.1178.90 | Non Steroidal Mineralcorticoid Receptor Antagonist |
2.16.840.1.113762.1.4.1178.91 | Glucagon like peptide 1 medications |
2.16.840.1.113762.1.4.1186.1 | Common drug substances for allergy and intolerance documentation |
2.16.840.1.113762.1.4.1186.7 | Common substances for allergy and intolerance documentation |
2.16.840.1.113762.1.4.1186.8 | Common substances for allergy and intolerance documentation including refutations |
2.16.840.1.113762.1.4.1190.58 | Diabetes Medications |
2.16.840.1.113762.1.4.1190.76 | Fidaxomicin |
2.16.840.1.113762.1.4.1190.77 | Vancomycin |
2.16.840.1.113762.1.4.1190.78 | Metronidazole |
2.16.840.1.113762.1.4.1190.79 | Fidaxomicin, Vancomycin, and Metronidazole |
2.16.840.1.113762.1.4.1190.85 | Baloxavir |
2.16.840.1.113762.1.4.1190.86 | Peramivir |
2.16.840.1.113762.1.4.1190.87 | Zanamivir |
2.16.840.1.113762.1.4.1190.90 | NHSN LTC AU Antimicrobial Agents |
2.16.840.1.113762.1.4.1196.1354 | Cefixime preparations for oral administration |
2.16.840.1.113762.1.4.1196.1370 | Beta lactam ingredients for allergy determination RXNORM |
2.16.840.1.113762.1.4.1196.158 | Multiple Myeloma Regimen Drugs |
2.16.840.1.113762.1.4.1196.226 | Opioids, All |
2.16.840.1.113762.1.4.1196.393 | Hypoglycemics Severe Hypoglycemia |
2.16.840.1.113762.1.4.1196.394 | Hypoglycemics Treatment Medications |
2.16.840.1.113762.1.4.1196.4436 | Gentamicin medications |
2.16.840.1.113762.1.4.1196.4437 | Azithromycin medications |
2.16.840.1.113762.1.4.1196.4448 | Lidocaine |
2.16.840.1.113762.1.4.1196.4469 | Cabotegravir Injectable Products |
2.16.840.1.113762.1.4.1196.4470 | Emtricitabine oral for HIV PrEP |
2.16.840.1.113762.1.4.1196.4502 | Ceftriaxone all code types |
2.16.840.1.113762.1.4.1196.491 | Medium Dose ICS Formoterol Preparations |
2.16.840.1.113762.1.4.1196.495 | ICS LABA LAMA Preparations |
2.16.840.1.113762.1.4.1196.93 | CPIC RxNORM abacavir SCDG |
2.16.840.1.113762.1.4.1196.94 | CPIC RxNORM allopurinol SCDG |
2.16.840.1.113762.1.4.1196.95 | CPIC RxNORM amitriptyline SCDG |
2.16.840.1.113762.1.4.1196.96 | CPIC RxNORM atazanavir SCDG |
2.16.840.1.113762.1.4.1196.97 | CPIC RxNORM atomoxetine SCDG |
2.16.840.1.113762.1.4.1196.99 | CPIC RxNORM capecitabine SCDG |
2.16.840.1.113762.1.4.1206.12 | Opioid (Oral Tablets and Patches only) |
2.16.840.1.113762.1.4.1206.19 | Anticoagulant Medications |
2.16.840.1.113762.1.4.1206.20 | Anticoagulant Medications, Oral |
2.16.840.1.113762.1.4.1206.21 | Anticoagulant Medications, Injection |
2.16.840.1.113762.1.4.1206.29 | Fall Risk Increasing Drugs (FRIDs) |
2.16.840.1.113762.1.4.1206.41 | TricyclicAntidepressants |
2.16.840.1.113762.1.4.1206.42 | Benzodiazepines |
2.16.840.1.113762.1.4.1206.43 | LoopDiuretics |
2.16.840.1.113762.1.4.1206.44 | Antiepileptics |
2.16.840.1.113762.1.4.1206.45 | Antipsychotics |
2.16.840.1.113762.1.4.1206.46 | Opioid Medications |
2.16.840.1.113762.1.4.1206.48 | Anticoagulant Medication |
2.16.840.1.113762.1.4.1206.50 | Bisphosphonate Therapy |
2.16.840.1.113762.1.4.1213.101 | Local Anesthetics |
2.16.840.1.113762.1.4.1213.102 | Ophthalmic Epinephrines |
2.16.840.1.113762.1.4.1213.103 | Inhaled Epinephrines |
2.16.840.1.113762.1.4.1213.104 | Clopidogrels |
2.16.840.1.113762.1.4.1213.105 | Cytochrome P450 2C19 inhibitors |
2.16.840.1.113762.1.4.1213.106 | Cytochrome P450 2C9 inhibitors |
2.16.840.1.113762.1.4.1213.107 | Aspirin Ingredient and Risk of GI Bleeding |
2.16.840.1.113762.1.4.1213.109 | Oral Anticoagulant Ingredients and Risk of GI Bleeding |
2.16.840.1.113762.1.4.1213.110 | Corticosteroid Ingredients and Risk of GI Bleeding |
2.16.840.1.113762.1.4.1213.111 | Antidepressant Ingredients and Risk of GI Bleeding |
2.16.840.1.113762.1.4.1213.112 | PPI and Risk of GI Bleeding |
2.16.840.1.113762.1.4.1213.113 | Antiplatelet Ingredients and Risk of GI Bleeding |
2.16.840.1.113762.1.4.1213.114 | NSAIDs Ingredients and Risk of GI Bleeding |
2.16.840.1.113762.1.4.1213.117 | Clopidogrel Ingredients and Risk of GI Bleeding |
2.16.840.1.113762.1.4.1213.24 | Oxycodones |
2.16.840.1.113762.1.4.1219.192 | Immunosuppressive Medication RxNorm |
2.16.840.1.113762.1.4.1219.193 | Medication Supporting Immunosupressive Medication RxNorm |
2.16.840.1.113762.1.4.1219.197 | Turalio |
2.16.840.1.113762.1.4.1219.85 | Insulin Medication |
2.16.840.1.113762.1.4.1221.176 | Methotrexate Injection |
2.16.840.1.113762.1.4.1221.177 | Mifepristone |
2.16.840.1.113762.1.4.1221.178 | Misoprostol |
2.16.840.1.113762.1.4.1221.179 | Abortion Medications |
2.16.840.1.113762.1.4.1221.183 | Clomiphene (Selective Estrogen Receptor Modulator / SERM) |
2.16.840.1.113762.1.4.1221.184 | Letrozole (Aromatase inhibitor) |
2.16.840.1.113762.1.4.1221.185 | Infertility, Female Medications |
2.16.840.1.113762.1.4.1221.209 | Transfeminine Regimens, Antiandrogens |
2.16.840.1.113762.1.4.1221.210 | Transfeminine Regimens, Estrogens |
2.16.840.1.113762.1.4.1221.211 | Transfeminine Regimens, GnRH Agonists |
2.16.840.1.113762.1.4.1221.212 | Transfeminine Regimens, All |
2.16.840.1.113762.1.4.1221.213 | Transmasculine Regimens, Testosterone, Transdermal |
2.16.840.1.113762.1.4.1221.214 | Transmasculine Regimens, Testosterone, Parenteral |
2.16.840.1.113762.1.4.1221.215 | Transmasculine Regimens, All |
2.16.840.1.113762.1.4.1235.264 | Heart Failure (CHF)_RxNorm |
2.16.840.1.113762.1.4.1235.265 | Heart Failure (CHF)_Clinical Condition Grouping |
2.16.840.1.113762.1.4.1235.342 | AFib (Atrial Fibrillation)_RxNORM |
2.16.840.1.113762.1.4.1235.344 | AFib (Atrial Fibrillation)_Clinical Condition Grouping |
2.16.840.1.113762.1.4.1235.348 | COVID19 Vaccine_RxNorm |
2.16.840.1.113762.1.4.1235.350 | COVID19 Vaccine_Event Clinical Grouping |
2.16.840.1.113762.1.4.1235.363 | Statin Use_RxNorm |
2.16.840.1.113762.1.4.1235.379 | Estrogen Agonists Medications_RXNORM |
2.16.840.1.113762.1.4.1235.638 | b.well Adult Tetanus Vaccine CN |
2.16.840.1.113762.1.4.1235.644 | BWellAdultTetanusVaccineCN_RxNorm |
2.16.840.1.113762.1.4.1237.18 | Medication Prescribable Brand Name |
2.16.840.1.113762.1.4.1237.22 | Medicinal Ingredients RXNORM |
2.16.840.1.113762.1.4.1248.119 | Opioid Antagonist |
2.16.840.1.113762.1.4.1248.120 | Opioids |
2.16.840.1.113762.1.4.1248.124 | Immune Modulators |
2.16.840.1.113762.1.4.1248.134 | Central Nervous System Depressants |
2.16.840.1.113762.1.4.1248.163 | Antidepressants |
2.16.840.1.113762.1.4.1248.164 | Antihypertensives |
2.16.840.1.113762.1.4.1248.170 | Diuretics |
2.16.840.1.113762.1.4.1248.204 | VTE Prophylaxis |
2.16.840.1.113762.1.4.1248.22 | Anticoagulants for All Indications |
2.16.840.1.113762.1.4.1248.230 | PO Antibacterials |
2.16.840.1.113762.1.4.1248.231 | Injectable Antifungals |
2.16.840.1.113762.1.4.1248.260 | Rivaroxaban Anticoagulant |
2.16.840.1.113762.1.4.1248.262 | Fondaparinux Anticoagulant |
2.16.840.1.113762.1.4.1248.263 | Dalteparin Anticoagulant |
2.16.840.1.113762.1.4.1248.264 | Heparin |
2.16.840.1.113762.1.4.1248.268 | Enoxaparin Anticoagulant |
2.16.840.1.113762.1.4.1248.352 | Androgen Deprivation Therapy for Urology Care |
2.16.840.1.113762.1.4.1248.353 | Bacillus Calmette Guerin for Urology Care |
2.16.840.1.113762.1.4.1248.355 | Chemotherapy Agents for Advanced Cancer |
2.16.840.1.113762.1.4.1248.364 | Immunosuppressive Drugs for Urology Care |
2.16.840.1.113762.1.4.1259.2 | Prescribable brand and generic non insulin drugs for hyperglycemia in Type 2 Diabetes |
2.16.840.1.113762.1.4.1259.3 | Prescribable brand and generic insulins and analogues |
2.16.840.1.113762.1.4.1259.9 | IgE Agonists, prescribable |
2.16.840.1.113762.1.4.1260.101 | Systemic Cancer Directed Therapy |
2.16.840.1.113762.1.4.1260.104 | Erdafitinib |
2.16.840.1.113762.1.4.1260.111 | Prior Therapies for Erdafitinib |
2.16.840.1.113762.1.4.1260.14 | Endocrine Therapy |
2.16.840.1.113762.1.4.1260.173 | Non Opioid Analgesics |
2.16.840.1.113762.1.4.1260.174 | Adjuvant Analgesics |
2.16.840.1.113762.1.4.1260.179 | Prior Therapies for Osimertinib |
2.16.840.1.113762.1.4.1260.182 | All Antineoplastic Agents |
2.16.840.1.113762.1.4.1260.207 | Osimertinib |
2.16.840.1.113762.1.4.1260.208 | Pemetrexed |
2.16.840.1.113762.1.4.1260.219 | Tepotinib |
2.16.840.1.113762.1.4.1260.230 | All Cancer Directed therapies |
2.16.840.1.113762.1.4.1260.249 | pralsetinib |
2.16.840.1.113762.1.4.1260.250 | Repotrectinib Value set |
2.16.840.1.113762.1.4.1260.251 | Amivantamab |
2.16.840.1.113762.1.4.1260.252 | Alectinib Drug |
2.16.840.1.113762.1.4.1260.253 | Gemcitabine Drug Value set |
2.16.840.1.113762.1.4.1260.254 | vinorelbine Drug |
2.16.840.1.113762.1.4.1260.275 | tarlatamab dlle |
2.16.840.1.113762.1.4.1260.284 | Binimetinib |
2.16.840.1.113762.1.4.1260.285 | Encorafenib |
2.16.840.1.113762.1.4.1260.292 | Prior therapy for Amivantamab |
2.16.840.1.113762.1.4.1260.293 | ENHERTU Drug |
2.16.840.1.113762.1.4.1260.321 | Prior_Systemic_therapy_Enhertu |
2.16.840.1.113762.1.4.1260.326 | Prior_systemic_therapy_Retevmo |
2.16.840.1.113762.1.4.1260.327 | Selpercatinib (Retevmo) Drug |
2.16.840.1.113762.1.4.1260.341 | Aromatase_Inhibitor therapy |
2.16.840.1.113762.1.4.1260.342 | Capivasertib_therapy |
2.16.840.1.113762.1.4.1260.343 | Fulvestrant_therapy |
2.16.840.1.113762.1.4.1260.363 | Trodelvy |
2.16.840.1.113762.1.4.1260.364 | Chemotherapy_breast_cancer |
2.16.840.1.113762.1.4.1260.365 | Cyclin_dependent_kinase |
2.16.840.1.113762.1.4.1260.366 | Taxane_Trodelvy |
2.16.840.1.113762.1.4.1260.367 | Endocrine_therapy |
2.16.840.1.113762.1.4.1260.400 | Fluoropyrimidine_CRC |
2.16.840.1.113762.1.4.1260.401 | Oxaliplatin |
2.16.840.1.113762.1.4.1260.402 | Irinotecan_based_therapy |
2.16.840.1.113762.1.4.1260.403 | anti_VEGF_therapy_CRC |
2.16.840.1.113762.1.4.1260.404 | anti_EGFR_therapy_CRC |
2.16.840.1.113762.1.4.1260.405 | fruquitinib |
2.16.840.1.113762.1.4.1260.419 | Adagrasib |
2.16.840.1.113762.1.4.1260.420 | cetuximab_therapy |
2.16.840.1.113762.1.4.1260.421 | Tamoxifen_therapy |
2.16.840.1.113762.1.4.1260.436 | Prior_therapy_Endometrial |
2.16.840.1.113762.1.4.1260.437 | Paclitaxel_therapy |
2.16.840.1.113762.1.4.1260.441 | Carboplatin_therapy |
2.16.840.1.113762.1.4.1260.442 | Durvalumab_therapy |
2.16.840.1.113762.1.4.1260.467 | Prior_Systemic_therapy_Repotrectinib |
2.16.840.1.113762.1.4.1260.47 | Systemic treatment for endometrial cancer |
2.16.840.1.113762.1.4.1260.470 | Tamoxifen_Trodelvy |
2.16.840.1.113762.1.4.1260.471 | Toremifene_trodelvy |
2.16.840.1.113762.1.4.1260.472 | Fulvestrant_Trodelvy |
2.16.840.1.113762.1.4.1260.473 | Elacestrant |
2.16.840.1.113762.1.4.1260.474 | Anastrozole_Trodelvy |
2.16.840.1.113762.1.4.1260.475 | Leuprolide_Trodelvy |
2.16.840.1.113762.1.4.1260.476 | Abemaciclib |
2.16.840.1.113762.1.4.1260.477 | Palbociclib |
2.16.840.1.113762.1.4.1260.478 | Ribociclib |
2.16.840.1.113762.1.4.1260.479 | Carboplatin_Trodelvy |
2.16.840.1.113762.1.4.1260.480 | Cisplatin_Trodelvy |
2.16.840.1.113762.1.4.1260.481 | Cyclophosphamide |
2.16.840.1.113762.1.4.1260.482 | Methotrexate |
2.16.840.1.113762.1.4.1260.483 | Gemcitabine |
2.16.840.1.113762.1.4.1260.484 | Capecitabine |
2.16.840.1.113762.1.4.1260.485 | Eribulin |
2.16.840.1.113762.1.4.1260.486 | Doxorubicin |
2.16.840.1.113762.1.4.1260.487 | Vinorelbine |
2.16.840.1.113762.1.4.1260.488 | Epirubicin |
2.16.840.1.113762.1.4.1260.489 | Ixabepilone |
2.16.840.1.113762.1.4.1260.490 | Olaparib |
2.16.840.1.113762.1.4.1260.491 | Talazoparib |
2.16.840.1.113762.1.4.1260.492 | Entrectinib |
2.16.840.1.113762.1.4.1260.493 | larotrectinib |
2.16.840.1.113762.1.4.1260.494 | Alpelisib |
2.16.840.1.113762.1.4.1260.495 | Capivasertib |
2.16.840.1.113762.1.4.1260.496 | Pembrolizumab |
2.16.840.1.113762.1.4.1260.497 | Dostarlimab |
2.16.840.1.113762.1.4.1260.498 | Selpercatinib |
2.16.840.1.113762.1.4.1260.499 | Everolimus |
2.16.840.1.113762.1.4.1260.500 | Trastuzumab_deruxtecan |
2.16.840.1.113762.1.4.1260.508 | High Emetogenic Risk Chemotherapy |
2.16.840.1.113762.1.4.1260.6 | Orserdu |
2.16.840.1.113762.1.4.1260.68 | Jemperli |
2.16.840.1.113762.1.4.1260.71 | Platinum based therapy |
2.16.840.1.113762.1.4.1260.72 | Prior Therapies for Tucatinib |
2.16.840.1.113762.1.4.1260.73 | Tucatinib |
2.16.840.1.113762.1.4.1264.25 | Antibiotic Usage for CAP Diagnosis |
2.16.840.1.113762.1.4.1264.29 | Broad Spectrum Antibiotics for MDRO |
2.16.840.1.113762.1.4.1264.39 | Antibiotic Usage for CAP Duration |
2.16.840.1.113762.1.4.1264.8 | Systemic Antimicrobials |
2.16.840.1.113762.1.4.1272.9 | Hormone Therapy |
2.16.840.1.113762.1.4.1289.1 | RXNormSBD0305 |
2.16.840.1.113762.1.4.1289.2 | RXNormSCD0305 |
2.16.840.1.113883.11.20.9.91 | Rho(D) Immune Globulin |
2.16.840.1.113883.3.117.1.7.1.134 | Oral Factor Xa Inhibitor for VTE Prophylaxis or VTE Treatment |
2.16.840.1.113883.3.117.1.7.1.200 | Anticoagulant Therapy |
2.16.840.1.113883.3.117.1.7.1.201 | Antithrombotic Therapy Anticoagulant |
2.16.840.1.113883.3.117.1.7.1.205 | Direct Thrombin Inhibitor |
2.16.840.1.113883.3.117.1.7.1.211 | Injectable Factor Xa Inhibitor for VTE Prophylaxis |
2.16.840.1.113883.3.117.1.7.1.218 | Unfractionated Heparin |
2.16.840.1.113883.3.117.1.7.1.219 | Low Molecular Weight Heparin for VTE Prophylaxis |
2.16.840.1.113883.3.117.1.7.1.226 | Thrombolytic tPA Therapy |
2.16.840.1.113883.3.117.1.7.1.232 | Warfarin |
2.16.840.1.113883.3.117.1.7.1.423 | Statin Allergen |
2.16.840.1.113883.3.1444.3.100 | Injectable Fluorouracil |
2.16.840.1.113883.3.1444.3.101 | Trastuzumab and Biosimilars |
2.16.840.1.113883.3.1444.3.105 | Long Acting Opioids |
2.16.840.1.113883.3.1444.3.122 | Carmustine Injectable |
2.16.840.1.113883.3.1444.3.123 | Dacarbazine Injectable |
2.16.840.1.113883.3.1444.3.124 | Streptozocin Injectable |
2.16.840.1.113883.3.1444.3.126 | Alemtuzumab Injectable |
2.16.840.1.113883.3.1444.3.127 | Azacitidine Injectable |
2.16.840.1.113883.3.1444.3.128 | Bendamustine Injectable |
2.16.840.1.113883.3.1444.3.129 | Busulfan Injectable |
2.16.840.1.113883.3.1444.3.130 | Temozolomide Injectable |
2.16.840.1.113883.3.1444.3.131 | Thiotepa Injectable |
2.16.840.1.113883.3.1444.3.132 | Oxaliplatin Injectable |
2.16.840.1.113883.3.1444.3.133 | Romidepsin Injectable |
2.16.840.1.113883.3.1444.3.134 | Trabectedin Injectable |
2.16.840.1.113883.3.1444.3.135 | Dolasetron Oral |
2.16.840.1.113883.3.1444.3.136 | Dolasetron Injectable |
2.16.840.1.113883.3.1444.3.137 | Granisetron Oral |
2.16.840.1.113883.3.1444.3.138 | Granisetron Transdermal |
2.16.840.1.113883.3.1444.3.139 | Granisetron Injectable |
2.16.840.1.113883.3.1444.3.140 | Ondansetron Oral |
2.16.840.1.113883.3.1444.3.141 | Ondansetron Injectable |
2.16.840.1.113883.3.1444.3.142 | Ifosfamide Injectable |
2.16.840.1.113883.3.1444.3.143 | Arsenic Trioxide Injectable |
2.16.840.1.113883.3.1444.3.144 | Netupitant Palonosetron Oral |
2.16.840.1.113883.3.1444.3.145 | Fosnetupitant Palonosetron Injectable |
2.16.840.1.113883.3.1444.3.146 | Aprepitant Injectable |
2.16.840.1.113883.3.1444.3.147 | Rolapitant Injectable |
2.16.840.1.113883.3.1444.3.148 | Dexamethasone Oral |
2.16.840.1.113883.3.1444.3.149 | Dexamethasone Injectable |
2.16.840.1.113883.3.1444.3.150 | Dexamethasone Drug Implant |
2.16.840.1.113883.3.1444.3.151 | Olanzapine Oral |
2.16.840.1.113883.3.1444.3.152 | Olanzapine Injectable |
2.16.840.1.113883.3.1444.3.153 | Idarubicin Injectable |
2.16.840.1.113883.3.1444.3.154 | Neurokinin 1 Receptor Antagonist Ingredient |
2.16.840.1.113883.3.1444.3.155 | Serotonin Receptor Antagonist Ingredient |
2.16.840.1.113883.3.1444.3.156 | Clofarabine Injectable |
2.16.840.1.113883.3.1444.3.157 | Belinostat Injectable |
2.16.840.1.113883.3.1444.3.158 | Bortezomib Injectable |
2.16.840.1.113883.3.1444.3.159 | Cabazitaxel Injectable |
2.16.840.1.113883.3.1444.3.160 | Carfilzomib Injectable |
2.16.840.1.113883.3.1444.3.161 | Decitabine Injectable |
2.16.840.1.113883.3.1444.3.162 | Elotuzumab Injectable |
2.16.840.1.113883.3.1444.3.163 | Enfortumab Injectable |
2.16.840.1.113883.3.1444.3.164 | Eribulin Injectable |
2.16.840.1.113883.3.1444.3.165 | Etoposide Injectable |
2.16.840.1.113883.3.1444.3.166 | Inotuzumab Ozogamicin Injectable |
2.16.840.1.113883.3.1444.3.167 | Mitoxantrone Injectable |
2.16.840.1.113883.3.1444.3.168 | Moxetumomab Injectable |
2.16.840.1.113883.3.1444.3.169 | Necitumumab Injectable |
2.16.840.1.113883.3.1444.3.170 | Nelarabine Injectable |
2.16.840.1.113883.3.1444.3.171 | Temsirolimus Injectable |
2.16.840.1.113883.3.1444.3.172 | Tisagenlecleucel Injectable |
2.16.840.1.113883.3.1444.3.173 | Topotecan Injectable |
2.16.840.1.113883.3.1444.3.178 | Atezolizumab Injectable |
2.16.840.1.113883.3.1444.3.179 | Avelumab Injectable |
2.16.840.1.113883.3.1444.3.180 | Bleomycin Injectable |
2.16.840.1.113883.3.1444.3.181 | Cemiplimab Injectable |
2.16.840.1.113883.3.1444.3.182 | Cladribine Injectable |
2.16.840.1.113883.3.1444.3.183 | Daratumumab Injectable |
2.16.840.1.113883.3.1444.3.184 | Durvalumab Injectable |
2.16.840.1.113883.3.1444.3.185 | Emapalumab Injectable |
2.16.840.1.113883.3.1444.3.186 | Fludarabine Injectable |
2.16.840.1.113883.3.1444.3.187 | Ipilimumab Injectable |
2.16.840.1.113883.3.1444.3.188 | Nivolumab Injectable |
2.16.840.1.113883.3.1444.3.189 | Pembrolizumab Injectable |
2.16.840.1.113883.3.1444.3.190 | Polatuzumab Vedotin Injectable |
2.16.840.1.113883.3.1444.3.191 | Pralatrexate Injectable |
2.16.840.1.113883.3.1444.3.192 | Vincristine Injectable |
2.16.840.1.113883.3.1444.3.193 | Methotrexate Injectable |
2.16.840.1.113883.3.1444.3.194 | Trastuzumab Injectable |
2.16.840.1.113883.3.1444.3.195 | Mitomycin Injectable |
2.16.840.1.113883.3.1444.3.196 | Brentuximab Vedotin Injectable |
2.16.840.1.113883.3.1444.3.197 | Doxorubicin Pegylated Liposomal Injectable |
2.16.840.1.113883.3.1444.3.198 | Blinatumomab Injectable |
2.16.840.1.113883.3.1444.3.199 | Trastuzumab Emtansine Injectable |
2.16.840.1.113883.3.1444.3.200 | Gemtuzumab Ozogamicin Injectable |
2.16.840.1.113883.3.1444.3.201 | Tagraxofusp Injectable |
2.16.840.1.113883.3.1444.3.202 | Axicabtagene Ciloleucel Injectable |
2.16.840.1.113883.3.1444.3.222 | High Emetic Risk Intravenous Antineoplastic Agent |
2.16.840.1.113883.3.1444.3.223 | Moderate Emetic Risk Intravenous Antineoplastic Agent |
2.16.840.1.113883.3.1444.3.224 | Docetaxel Injectable |
2.16.840.1.113883.3.1444.3.225 | Cyclophosphamide Injectable |
2.16.840.1.113883.3.1444.3.226 | LAG 3 Inhibitor |
2.16.840.1.113883.3.1444.3.242 | Moderate or High Emetic Risk Oral Antineoplastic Agent |
2.16.840.1.113883.3.1444.3.243 | Minimal to Low Emetic Risk Oral Antineoplastic Agent |
2.16.840.1.113883.3.1444.3.244 | Copanlisib Injectable |
2.16.840.1.113883.3.1444.3.245 | Isatuximab Injectable |
2.16.840.1.113883.3.1444.3.246 | Loncastuximab tesirine Injectable |
2.16.840.1.113883.3.1444.3.247 | Margetuximab Injectable |
2.16.840.1.113883.3.1444.3.248 | Mirvetuximab soravtansine Injectable |
2.16.840.1.113883.3.1444.3.249 | Tafasitamab Injectable |
2.16.840.1.113883.3.1444.3.250 | Teclistamab Injectable |
2.16.840.1.113883.3.1444.3.251 | Tisotumab Injectable |
2.16.840.1.113883.3.1444.3.252 | Asparaginase Injectable |
2.16.840.1.113883.3.1444.3.254 | Belantamab Injectable |
2.16.840.1.113883.3.1444.3.255 | Dostarlimab Injectable |
2.16.840.1.113883.3.1444.3.256 | Mosunetuzumab Injectable |
2.16.840.1.113883.3.1444.3.257 | Tremelimumab Injectable |
2.16.840.1.113883.3.1444.3.264 | Prednisone |
2.16.840.1.113883.3.1444.3.266 | Amivantamab Injectable |
2.16.840.1.113883.3.1444.5.200 | Doxorubicin |
2.16.840.1.113883.3.1444.5.201 | Epirubicin |
2.16.840.1.113883.3.1444.5.202 | Capecitabine |
2.16.840.1.113883.3.1444.5.203 | Cyclophosphamide |
2.16.840.1.113883.3.1444.5.204 | Injectable Fluorouracil |
2.16.840.1.113883.3.1444.5.205 | Methotrexate |
2.16.840.1.113883.3.1444.5.206 | Trastuzumab and Biosimilars |
2.16.840.1.113883.3.1444.5.208 | Carboplatin |
2.16.840.1.113883.3.1444.5.210 | Long Acting Opioids |
2.16.840.1.113883.3.1444.5.212 | Dexamethasone |
2.16.840.1.113883.3.1444.5.213 | Olanzapine |
2.16.840.1.113883.3.1444.5.228 | Low Emetic Risk Intravenous Antineoplastic Agent |
2.16.840.1.113883.3.1444.5.229 | Minimal Emetic Risk Intravenous Antineoplastic Agent |
2.16.840.1.113883.3.1444.5.238 | First Line Drug Therapy for Metastatic Colorectal Cancer |
2.16.840.1.113883.3.1444.5.242 | High Emetic Risk Intravenous Antineoplastic Agent |
2.16.840.1.113883.3.1444.5.243 | Moderate Emetic Risk Intravenous Antineoplastic Agent |
2.16.840.1.113883.3.1444.5.244 | Anthracycline Injectable |
2.16.840.1.113883.3.1444.5.245 | Antiemetic Agent |
2.16.840.1.113883.3.3157.1002.11 | Oxycodone |
2.16.840.1.113883.3.3157.1002.12 | Oxymorphone |
2.16.840.1.113883.3.3157.1002.70 | Morphine |
2.16.840.1.113883.3.3157.1002.71 | Methadone Medications |
2.16.840.1.113883.3.3157.1002.72 | Meperidine |
2.16.840.1.113883.3.3157.1002.73 | Levorphanol |
2.16.840.1.113883.3.3157.1002.74 | Hydromorphone |
2.16.840.1.113883.3.3157.1002.75 | Hydrocodone |
2.16.840.1.113883.3.3157.1002.76 | Fentanyl |
2.16.840.1.113883.3.3157.1002.77 | Codeine |
2.16.840.1.113883.3.3157.1004.12 | Butorphanol |
2.16.840.1.113883.3.3157.1004.13 | Dihydrocodeine |
2.16.840.1.113883.3.3157.1004.14 | Nalbuphine |
2.16.840.1.113883.3.3157.1004.15 | Opium Combinations |
2.16.840.1.113883.3.3157.1004.16 | Pentazocine |
2.16.840.1.113883.3.3157.1004.17 | Tapentadol |
2.16.840.1.113883.3.3157.1004.18 | Tramadol |
2.16.840.1.113883.3.3157.4019 | Fibrinolytic Therapy |
2.16.840.1.113883.3.3157.4045 | Oral Anticoagulant Medications |
2.16.840.1.113883.3.464.1003.1043 | Potentially Harmful Antihistamines for Older Adults |
2.16.840.1.113883.3.464.1003.1049 | Potentially Harmful Antiparkinsonian Agents for Older Adults |
2.16.840.1.113883.3.464.1003.1050 | Potentially Harmful Gastrointestinal Antispasmodics for Older Adults |
2.16.840.1.113883.3.464.1003.1051 | Dipyridamole Medications |
2.16.840.1.113883.3.464.1003.1053 | Nifedipine Medications |
2.16.840.1.113883.3.464.1003.1054 | Potentially Harmful Antidepressants for Older Adults |
2.16.840.1.113883.3.464.1003.1055 | Potentially Harmful Barbiturates for Older Adults |
2.16.840.1.113883.3.464.1003.1057 | Meprobamate Medications |
2.16.840.1.113883.3.464.1003.1058 | Potentially Harmful Estrogens for Older Adults |
2.16.840.1.113883.3.464.1003.1059 | Potentially Harmful Sulfonylureas for Older Adults |
2.16.840.1.113883.3.464.1003.1060 | Desiccated Thyroid Medications |
2.16.840.1.113883.3.464.1003.1062 | Potentially Harmful Skeletal Muscle Relaxants for Older Adults |
2.16.840.1.113883.3.464.1003.1063 | Potentially Harmful Pain Medications for Older Adults |
2.16.840.1.113883.3.464.1003.1065 | Digoxin Medications |
2.16.840.1.113883.3.464.1003.1066 | Digoxin Medications |
2.16.840.1.113883.3.464.1003.1067 | Doxepin Medications |
2.16.840.1.113883.3.464.1003.1068 | Doxepin Medications |
2.16.840.1.113883.3.464.1003.1149 | Substance Use Disorder Long Acting Medication |
2.16.840.1.113883.3.464.1003.1150 | Substance Use Disorder Short Acting Medication |
2.16.840.1.113883.3.464.1003.1170 | Atomoxetine |
2.16.840.1.113883.3.464.1003.1171 | Clonidine |
2.16.840.1.113883.3.464.1003.1172 | Dexmethylphenidate |
2.16.840.1.113883.3.464.1003.1173 | Dextroamphetamine |
2.16.840.1.113883.3.464.1003.1174 | Lisdexamfetamine |
2.16.840.1.113883.3.464.1003.1176 | Methylphenidate |
2.16.840.1.113883.3.464.1003.1190 | Antibiotic Medications for Upper Respiratory Infection |
2.16.840.1.113883.3.464.1003.1247 | Megestrol Medications |
2.16.840.1.113883.3.464.1003.1248 | Meperidine Medications |
2.16.840.1.113883.3.464.1003.1249 | Potentially Harmful Antidepressants for Older Adults |
2.16.840.1.113883.3.464.1003.1250 | Potentially Harmful Antihistamines for Older Adults |
2.16.840.1.113883.3.464.1003.1251 | Potentially Harmful Antiparkinsonian Agents for Older Adults |
2.16.840.1.113883.3.464.1003.1252 | Potentially Harmful Barbiturates for Older Adults |
2.16.840.1.113883.3.464.1003.1253 | Potentially Harmful Estrogens for Older Adults |
2.16.840.1.113883.3.464.1003.1254 | Potentially Harmful Gastrointestinal Antispasmodics for Older Adults |
2.16.840.1.113883.3.464.1003.1255 | Potentially Harmful Pain Medications for Older Adults |
2.16.840.1.113883.3.464.1003.1256 | Potentially Harmful Skeletal Muscle Relaxants for Older Adults |
2.16.840.1.113883.3.464.1003.1257 | Potentially Harmful Sulfonylureas for Older Adults |
2.16.840.1.113883.3.464.1003.1258 | Substance Use Disorder Long Acting Medication |
2.16.840.1.113883.3.464.1003.1259 | Substance Use Disorder Short Acting Medication |
2.16.840.1.113883.3.464.1003.1260 | Viloxazine |
2.16.840.1.113883.3.464.1003.196.11.1001 | Antibiotic Medications for Pharyngitis |
2.16.840.1.113883.3.464.1003.196.11.1078 | Nifedipine Medications |
2.16.840.1.113883.3.464.1003.196.11.1080 | Contraceptive Medications |
2.16.840.1.113883.3.464.1003.196.11.1109 | Meperidine Medications |
2.16.840.1.113883.3.464.1003.196.11.1129 | Desiccated Thyroid Medications |
2.16.840.1.113883.3.464.1003.196.11.1143 | Isotretinoin |
2.16.840.1.113883.3.464.1003.196.11.1167 | Dipyridamole Medications |
2.16.840.1.113883.3.464.1003.196.11.1205 | Leucovorin |
2.16.840.1.113883.3.464.1003.196.11.1211 | Aspirin and Other Antiplatelets |
2.16.840.1.113883.3.464.1003.196.11.1252 | Guanfacine Medications |
2.16.840.1.113883.3.464.1003.196.11.1255 | Megestrol Medications |
2.16.840.1.113883.3.464.1003.196.11.1256 | Meprobamate Medications |
2.16.840.1.113883.3.464.1003.196.11.1266 | Aromatase Inhibitors |
2.16.840.1.113883.3.464.1003.196.11.1267 | Glucocorticoids (oral only) |
2.16.840.1.113883.3.464.1003.196.11.1481 | Potentially Harmful Nonbenzodiazepine Hypnotics for Older Adults |
2.16.840.1.113883.3.464.1003.196.11.1482 | Potentially Harmful Antiinfectives for Older Adults |
2.16.840.1.113883.3.464.1003.196.11.1517 | Dementia Medications |
2.16.840.1.113883.3.464.1003.196.11.1530 | Antidepressant Medication |
2.16.840.1.113883.3.464.1003.196.11.1531 | Potentially Harmful Benzodiazepines for Older Adults |
2.16.840.1.113883.3.464.1003.196.11.1532 | Potentially Harmful Antipsychotics for Older Adults |
2.16.840.1.113883.3.464.1003.196.12.1001 | Antibiotic Medications for Pharyngitis |
2.16.840.1.113883.3.464.1003.196.12.1080 | Contraceptive Medications |
2.16.840.1.113883.3.464.1003.196.12.1143 | Isotretinoin |
2.16.840.1.113883.3.464.1003.196.12.1205 | Leucovorin |
2.16.840.1.113883.3.464.1003.196.12.1211 | Aspirin and Other Antiplatelets |
2.16.840.1.113883.3.464.1003.196.12.1213 | Antidepressant Medication |
2.16.840.1.113883.3.464.1003.196.12.1265 | Aromatase Inhibitors |
2.16.840.1.113883.3.464.1003.196.12.1266 | Glucocorticoids (oral only) |
2.16.840.1.113883.3.464.1003.196.12.1480 | Potentially Harmful Nonbenzodiazepine Hypnotics for Older Adults |
2.16.840.1.113883.3.464.1003.196.12.1481 | Potentially Harmful Antiinfectives for Older Adults |
2.16.840.1.113883.3.464.1003.196.12.1510 | Dementia Medications |
2.16.840.1.113883.3.464.1003.196.12.1522 | Potentially Harmful Benzodiazepines for Older Adults |
2.16.840.1.113883.3.464.1003.196.12.1523 | Potentially Harmful Antipsychotics for Older Adults |
2.16.840.1.113883.3.526.1577 | Pharmacologic Therapy for Hypertension |
2.16.840.1.113883.3.526.2.133 | Beta Blocker Therapy |
2.16.840.1.113883.3.526.2.1342 | Beta Blocker Therapy for LVSD |
2.16.840.1.113883.3.526.2.1921 | Beta Blocker Therapy Ingredient |
2.16.840.1.113883.3.526.2.423 | Tobacco Use Cessation Pharmacotherapy |
2.16.840.1.113883.3.526.3.1139 | ACE Inhibitor or ARB or ARNI |
2.16.840.1.113883.3.526.3.1174 | Beta Blocker Therapy |
2.16.840.1.113883.3.526.3.1184 | Beta Blocker Therapy for LVSD |
2.16.840.1.113883.3.526.3.1190 | Tobacco Use Cessation Pharmacotherapy |
2.16.840.1.113883.3.526.3.1489 | ACE Inhibitor or ARB or ARNI Ingredient |
2.16.840.1.113883.3.526.3.1493 | Beta Blocker Therapy Ingredient |
2.16.840.1.113883.3.526.3.1561 | Medications for Above Normal BMI |
2.16.840.1.113883.3.526.3.1562 | Medications for Below Normal BMI |
2.16.840.1.113883.3.526.3.1566 | Adult Depression Medications |
2.16.840.1.113883.3.526.3.1567 | Adolescent Depression Medications |
2.16.840.1.113883.3.526.3.1572 | High Intensity Statin Therapy |
2.16.840.1.113883.3.526.3.1574 | Low Intensity Statin Therapy |
2.16.840.1.113883.3.526.3.1575 | Moderate Intensity Statin Therapy |
2.16.840.1.113883.3.526.3.3000 | Metformin |
2.16.840.1.113883.3.600.1.1498 | Medications for Above Normal BMI |
2.16.840.1.113883.3.600.1.1499 | Medications for Below Normal BMI |
2.16.840.1.113883.3.600.1476 | Pharmacologic Therapy for Hypertension |
2.16.840.1.113883.3.600.469 | Adolescent Depression Medications |
2.16.840.1.113883.3.600.470 | Adult Depression Medications |
2.16.840.1.113883.3.88.12.80.16 | Medication Brand Name |
2.16.840.1.113883.3.88.12.80.17 | Medication Clinical General Drug |
2.16.840.1.114222.4.11.3183 | NHSNSkinPreparationCode |
2.16.840.1.114222.4.11.3360 | NHSNAntimicrobialAgentAURPCode |